NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
RPG Life Sciences Q4 Revenue Jumps 23.6%, Recommends 300% Dividend
RPG Life Sciences reported a strong Q4 FY26 with revenue growing 23.6% YoY to ₹176.9 crores and a healthy EBITDA margin of 25.6%. The Domestic Formulations business outperformed the Indian Pharma Market by 1.8 times, growing at 18.2% in Q4. A significant highlight was the API division's 144.3% growth, marking a full recovery after operations were impacted by a fire in early 2025. The company also announced a substantial final dividend of ₹24 per share for the fiscal year.
முக்கிய அம்சங்கள்
Q4 FY26 Revenue rose 23.6% YoY to ₹176.9 crores with an EBITDA margin of 25.6%Domestic Formulations grew 18.2% in Q4, outpacing the Indian Pharma Market growth of 10.1%API division revenue surged 144.3% in Q4 FY26 following the restoration of the manufacturing facilityFull-year FY26 revenue reached ₹707.5 crores, up 8.3% from ₹653.4 crores in FY25Recommended a final dividend of ₹24 per equity share (300% on face value of ₹8)
👀 கவனிக்க வேண்டியவை
The stock remains attractive due to its consistent market-beating growth in domestic formulations and the successful turnaround of the API segment. Investors should monitor the company's expansion into new global markets and its new product pipeline for long-term value creation.
RPG Life Sciences Clarifies Identical Q3 Results; API Division Spin-off to Subsidiary Underway
RPG Life Sciences clarified to the NSE that its standalone and consolidated financial results for Q3 FY26 are identical because its new subsidiary, RPG Active Pharma Limited, only commenced operations on January 6, 2026. The company reported a Q3 revenue of ₹18,003 Lakhs and a Profit After Tax of ₹2,213 Lakhs. Results were impacted by a one-time exceptional charge of ₹1,108 Lakhs due to the implementation of New Labour Codes. The internal reorganization to transfer the API division is expected to be completed by February 2026 to streamline business focus.
முக்கிய அம்சங்கள்
Q3 FY26 Revenue from operations stood at ₹18,003 Lakhs, a growth from ₹17,271 Lakhs in the previous year's corresponding quarter.Net Profit for the quarter was ₹2,213 Lakhs, after accounting for a ₹1,108 Lakhs exceptional expense for New Labour Code obligations.The company is transferring its API division to a new wholly-owned subsidiary, RPG Active Pharma Limited, incorporated on December 24, 2025.Insurance recovery for the January 2025 fire incident is progressing, with ₹2,050 Lakhs received against a total loss of ₹2,295 Lakhs.Nine-month FY26 Revenue reached ₹53,063 Lakhs with a Net Profit of ₹8,527 Lakhs.
👀 கவனிக்க வேண்டியவை
Investors should monitor the completion of the API division transfer and its impact on operational efficiency. The exceptional hit from the New Labour Code is a one-time regulatory adjustment and does not reflect on core business performance.
RPG Life Sciences Q3 FY26: Revenue Up 4.2% to ₹180 Cr, PAT Declines 20% YoY
RPG Life Sciences reported a modest 4.2% YoY revenue growth in Q3 FY26, reaching ₹180 crore, primarily driven by a 12.5% growth in its Domestic Formulations segment. However, profitability faced significant pressure as PAT declined 20% YoY to ₹27.9 crore and EBITDA margins contracted from 30.4% to 24.0%. The API segment was particularly weak, with a 19.4% revenue decline in 9M FY26 due to a fire incident at a manufacturing block. Despite these headwinds, the company remains debt-free and is proceeding with a ₹140 crore capex plan for global expansion.
முக்கிய அம்சங்கள்
Q3 FY26 Revenue grew 4.2% YoY to ₹180 Cr, while 9M FY26 Revenue rose 4.0% to ₹530.6 Cr.PAT for Q3 FY26 dropped 20% YoY to ₹27.9 Cr, with EBITDA margins contracting to 24.0% from 30.4%.Domestic Formulations, contributing 70% of sales, grew 12.5% in 9M FY26, outperforming market growth.API segment revenue fell 19.4% in 9M FY26, impacted by a fire incident in one of the manufacturing blocks.The company maintains a debt-free balance sheet and is investing ₹140 Cr in capex to expand its international footprint.
👀 கவனிக்க வேண்டியவை
The significant margin contraction and the fire-related disruption in the API segment are short-term negatives. Investors should watch for the recovery of API operations and the impact of the ₹140 crore capex on future growth before increasing exposure.
RPG Life Sciences Approves Q3 FY26 Unaudited Financial Results
RPG Life Sciences Limited has officially approved its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The board meeting, held on January 27, 2026, concluded with the submission of these results along with the Statutory Auditor's Limited Review Report. While the specific profit and revenue figures were not detailed in the cover letter, the filing confirms compliance with SEBI Listing Obligations. Investors should now examine the full financial tables to evaluate the company's performance trajectory for the fiscal year.
முக்கிய அம்சங்கள்
Board approved unaudited financial results for the quarter ended December 31, 2025Consolidated and standalone results for the nine-month period were submitted to exchangesThe board meeting lasted three and a half hours, concluding at 6:30 p.m.Statutory auditors have provided a Limited Review Report for the period
👀 கவனிக்க வேண்டியவை
Investors should review the detailed profit and loss statements to assess margin trends and revenue growth compared to the previous year. Monitor the stock's price action in the coming sessions for the market's reaction to the specific earnings data.
RPG Life Sciences Incorporates Wholly Owned Subsidiary RPG Active Pharma Limited
RPG Life Sciences Limited has officially incorporated a new wholly owned subsidiary named RPG Active Pharma Limited on December 24, 2025. This move follows the company's prior intimation on December 15, 2025, regarding the strategic intent to form this entity. The new subsidiary is registered under CIN U21001MH2025PLC464091 and is expected to focus on specialized pharmaceutical operations. This structural expansion indicates a potential focus on the Active Pharmaceutical Ingredients (API) segment or a dedicated business vertical to drive future growth.
முக்கிய அம்சங்கள்
Incorporated a 100% wholly owned subsidiary named RPG Active Pharma Limited on December 24, 2025The new entity is registered under Corporate Identification Number (CIN) U21001MH2025PLC464091The incorporation follows a prior regulatory intimation dated December 15, 2025The move aligns with the company's long-term growth strategy within the pharmaceutical sector
👀 கவனிக்க வேண்டியவை
Investors should monitor future announcements regarding the specific business objectives and capital expenditure plans for this new subsidiary. This expansion could potentially enhance the company's manufacturing capabilities and market reach in the API segment.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
RPGLIFE: Key Managerial Personnel Authorized as of December 15, 2025
RPG Life Sciences has authorized key managerial personnel (KMP) for determining the materiality of events and for making disclosures to stock exchanges, effective December 15, 2025. Mr. Ashok Nair (Managing Director) and Mr. Amol Lone (Chief Financial Officer) are jointly authorized to determine materiality. For disclosures, Mr. Rajesh Shirambekar (Head- Legal & Company Secretary) is also authorized severally. Investors should note these changes in authorized personnel for company communications.
முக்கிய அம்சங்கள்
Mr. Ashok Nair is the Managing Director authorized for materiality determination.Mr. Amol Lone is the Chief Financial Officer authorized for materiality determination.Mr. Rajesh Shirambekar is the Head- Legal & Company Secretary authorized for disclosures.Authorization effective from December 15, 2025.
👀 கவனிக்க வேண்டியவை
Investors should take note of the authorized personnel for future communications and disclosures from the company. Monitor company announcements for any material events as determined by the authorized KMPs.
RPGLIFE appoints Amol Lone as CFO, to incorporate RPG Active Pharma
RPG Life Sciences has appointed Mr. Amol Lone as the Chief Financial Officer (CFO) effective December 15, 2025. The company will also incorporate a wholly-owned subsidiary, "RPG Active Pharma Limited," for manufacturing and marketing active pharmaceutical ingredients (API). RPGLIFE plans to transfer its existing API business, which contributed ₹90.24 crores (13.8%) to FY25 turnover, to the new subsidiary. An investment of up to ₹105 crore will be made in the WOS in one or more tranches.
முக்கிய அம்சங்கள்
Amol Lone appointed as CFO effective December 15, 2025API business contributed ₹90.24 crores to FY25 turnoverAPI business net worth as on March 31, 2025 was ₹90.61 croresInvestment of up to ₹105 crore in the new WOSConsideration for API business transfer expected to be approximately ₹50 crore
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of the API business transfer and the performance of the new subsidiary, RPG Active Pharma Limited. Keep an eye on how the ₹105 crore investment impacts the company's growth and profitability.
RPGLIFE Board approves API business transfer to new wholly-owned subsidiary
RPG Life Sciences' board approved the transfer of its API business, which contributed ₹90.24 crore (13.8%) to FY25 turnover, to a new wholly-owned subsidiary (WOS). The net worth of the API business as of March 31, 2025, was ₹90.61 crore, representing 17.1% of the company's total net worth. The company will invest up to ₹105 crore in the WOS in tranches. The consideration for the transfer is expected to be approximately ₹50 crore.
முக்கிய அம்சங்கள்
API business contributed ₹90.24 crore to FY25 turnover (13.8%).Net worth of API business was ₹90.61 crore as of March 31, 2025 (17.1% of total).Investment of up to ₹105 crore in the WOS.Consideration for API business transfer expected to be approximately ₹50 crore.
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of the API business transfer and the performance of the new subsidiary. Keep an eye on how the ₹105 crore investment impacts the company's growth.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
